Abstract:Esophageal Cancer-Related Gene 2 (ECRG2), also known as Serine Peptidase Inhibitor Kazal type 7 (SPINK7), is a novel tumor suppressor gene from the SPINK family of genes that exhibits anticancer potential. ECRG2 was originally identified during efforts to discover genes involved in esophageal tumorigenesis. ECRG2 was one of those genes whose expression was absent or reduced in primary human esophageal cancers. Additionally, absent or reduced ECRG2 expression was also noted in several other types of human malignancies. ECRG2 missense mutations were identified in various primary human cancers. It was reported that a cancer-derived ECRG2 mutant (valine to glutamic acid at position 30) failed to induce cell death and caspase activation triggered by DNA-damaging anticancer drugs. Furthermore, ECRG2 suppressed cancer cell proliferation in cultured cells and grafted tumors in animals and inhibited cancer cell migration/invasion and metastasis. ECRG2 also was identified as a negative regulator of Hu-antigen R (HuR), an oncogenic RNA-binding protein that is known to regulate mRNA stability and the expression of transcripts corresponding to many cancer-related genes. ECRG2 function is important also for the regulation of inflammatory responses and the maintenance of epithelial barrier integrity in the esophagus. More recently, ECRG2 was discovered as one of the newest members of the pro-apoptotic transcriptional targets of p53. Two p53-binding sites (BS-1 and BS-2) were found within the proximal region of the ECRG2 gene promoter; the treatment of DNA-damaging agents in cancer cells significantly increased p53 binding to the ECRG2 promoter and triggered a strong ECRG2 promoter induction following DNA damage. Further, the genetic depletion of ECRG2 expression significantly impeded apoptotic cell death induced by DNA damage and wild-type p53 in cancer cells. These findings suggest that the loss of ECRG2 expression, commonly observed in human cancers, could play important roles in conferring anticancer drug resistance in human cancers. Thus, ECRG2 is a novel regulator in DNA damage-induced cell death that may also be a potential target for anticancer therapeutics.

ECRG4 Acts As a Tumor Suppressor Gene Frequently Hypermethylated in Human Breast Cancer.

The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

Expression and Epigenetic Silencing of Ecrg4 Gene in Breast Cancer

[Expression and Function of ECRG4 in Hepatocellular Carcinoma].

ECRG4 As a Novel Tumor Suppressor Gene Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo

Downregulated ECRG4 is Associated with Poor Prognosis in Renal Cell Cancer and is Regulated by Promoter DNA Methylation

Expression of ECRG4, a Novel Esophageal Cancer-Related Gene, Downregulated by CpG Island Hypermethylation in Human Esophageal Squamous Cell Carcinoma

Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer

ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma

Eif4ebp3 Was Downregulated by Methylation and Acted As a Tumor Suppressor by Targeting Eif4e/β-Catenin in Gastric Cancer.

ECRG4 Inhibits Growth and Invasiveness of Squamous Cell Carcinoma of the Head and Neck in Vitro and in Vivo

Promoter methylation of esophageal cancer-related gene 4 in gastric cancer tissue and its clinical significance.

A potential role of human esophageal cancer-related gene-4 in cardiovascular homeostasis

CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer.

ECRG2/SPINK7 Tumor Suppressor as Modulator of DNA Damage Response

A Potential Link Between Aberrant Expression of ECRG4 and Atrial Fibrillation

Data from <i>CMTM3</i>, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis

RHCG Suppresses Tumorigenicity and Metastasis in Esophageal Squamous Cell Carcinoma via Inhibiting NF-κB Signaling and MMP1 Expression.

ECRG4 Represses Cell Proliferation and Invasiveness via NFIC/OGN/NF-κB Signaling Pathway in Bladder Cancer

Dysregulation of CXCL14 promotes malignant phenotypes of esophageal squamous carcinoma cells via regulating SRC and EGFR signaling